logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Sarepta Pharmaceuticals Jumps on Competitor’s Failure

  +Follow August 16, 2013 9:54AM
Share:
Tickers Mentioned:

Sarepta Therapeutics Inc. (SRPT) experienced a bit of schadenfreude on Aug. 16 as a direct competitor stumbled badly at the finish line.

Competitor GlaxoSmithKline plc (GSK) had been neck-and-neck with Serepta in the race to develop a breakthrough muscle disorder drug to treat Duchenne Muscular Dystrophy. Both drugs were far ahead of the pack in the development process.

That is, until Baird analyst Brian Skorney reported that Glaxo’s drug, drisapersen, has encountered major stumbling blocks on several fronts that could significantly hamper development. Skorney cited clinical, regulatory, and commercials issues with the drug. Most importantly, the drug did not seem to effectively treat symptoms of the disease at the targeted dose.

Serepta’s drug, eteplirsen, so far has seemed to be effective at treating symptoms of Duchenne. Clinical trials have taken place in the UK. On Aug. 7 the company released promising clinical trial information, which will form the basis of their application for US FDA approval in early 2014.

Duchenne is a severely debilitating form of muscular dystrophy. The recessive muscular degenerative disorder affects approximately 1 in 3,600 boys, and life expectancy for sufferers is usually around 25. A drug from either company would be the first on the American market designed to treat the disorder.

The London-based GlaxoSmithKline , which is the fourth largest pharmaceutical company in the world, shrugged off the setback. Their stock is up .33 percent to hit $51.70 a share.

Serepta is up 6.77 percent to hit $34.21 a share.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Signup for our daily newsletter and get our best articles emailed right to you!

Results for GSK
Bull Logic
2 Sep 15 16:57:17
RT @BioStocks: $GSK reports 24.5% stake in $TBPH
julienne demler
2 Sep 15 16:45:09
RT @ariadinvestor: $ARIA Baxalta rumored to have sweetened deal? $18/share? 1 m shares traded in first 30min $mrk $gsk $amgn $bxlt $shpg $c…
Mike Robinson
2 Sep 15 16:29:53
RT @lomu_j: $TBPH @BioStocks The $GSK position is not new FWIW. Same as in March http://t.co/iopFpJyeKn
John Turner
2 Sep 15 14:47:24
$GSK Should Gilead Sciences, Inc. Fear GlaxoSmithKline plc (ADR)? http://t.co/WmsoeKyFEq
Laura Cosma
2 Sep 15 13:57:46
RT @FiercePharma: $GSK hep B supplies to Japan hit by Tianjin explosion http://t.co/4e3txOMJu1
Thomas Collins
2 Sep 15 13:41:36
$GSK 52-Week Low Stocks To Watch : GlaxoSmithKline PLC (ADR) (NYSE:GSK), Mindray ... http://t.co/8igh8WDFik
Audi
2 Sep 15 13:27:46
RT @FiercePharma: $GSK hep B supplies to Japan hit by Tianjin explosion http://t.co/4e3txOMJu1
FiercePharmaAsia
2 Sep 15 13:05:09
$GSK hep B supplies to Japan hit by Tianjin explosion http://t.co/Y0iIlD3lDV
FiercePharma
2 Sep 15 13:05:09
$GSK hep B supplies to Japan hit by Tianjin explosion http://t.co/4e3txOMJu1
Steve Feffer
2 Sep 15 12:53:41
$TBPH NHOD... $GSK 25% stake and tiny float... get ready
V.S. Schulz
2 Sep 15 12:50:57
.@bradloncar @DewDiligence Don't forget $FOLD -> https://t.co/VsJ78u3Upo :) $GSK $SGMO $SHPG
Ariel Silahian
2 Sep 15 12:50:03
Algo trading: OPEN signals Sep/02 BUY: $IBN $BMY $REGN $DFS $PHG $MA $NCLH $ADI $TIF $PGR $PHH $PFE $EL $MTB $PAYX $DATA $IMGN $GSK $AERI
FinBuzz
2 Sep 15 12:35:26
Start with your free watchlist for #FTSE 100 $LLOY $GSK $BATS http://t.co/LfC1vQQyj2 http://t.co/e1rF2LXOcz
Seeking Alpha
2 Sep 15 12:17:56
Healthcare Dogs: 3.25% To 10.62% Dividend Yields From 10 As Of August 28 http://t.co/KkPdhTX8Sm $AZN $BAX $GSK $JNJ $MRK $PDLI $PETS $PFE
Healthcare Stocks
2 Sep 15 12:17:55
Healthcare Dogs: 3.25% To 10.62% Dividend Yields From 10 As Of August 28 http://t.co/ri2XvLB6Tf $AZN $BAX $GSK $JNJ $MRK $PDLI $PETS $PFE
Dividend Investing
2 Sep 15 12:17:55
Healthcare Dogs: 3.25% To 10.62% Dividend Yields From 10 As Of August 28 http://t.co/gFZPVZH8g7 $AZN $BAX $GSK $JNJ $MRK $PDLI $PETS $PFE
Income Investing SA
2 Sep 15 12:17:55
Healthcare Dogs: 3.25% To 10.62% Dividend Yields From 10 As Of August 28 http://t.co/jOY8HjeZTh $AZN $BAX $GSK $JNJ $MRK $PDLI $PETS $PFE
Seeking Alpha
2 Sep 15 12:17:54
Healthcare Dogs: 3.25% To 10.62% Dividend Yields From 10 As Of August 28 http://t.co/Moa11Gxh3U $AZN $BAX $GSK $JNJ $MRK $PDLI $PETS $PFE
DailyStockPicks
2 Sep 15 11:40:17
$ANFI spiking hard just like $ACI. 100%+ upside potential P/E of 3 $PCLN $COP $XLB $DTV $GSK $WY investors read http://t.co/L1jwUVoc1O
Ani Anirudhan
2 Sep 15 11:31:36
RT @lomu_j: $TBPH @BioStocks The $GSK position is not new FWIW. Same as in March http://t.co/iopFpJyeKn
V.S. Schulz
2 Sep 15 11:30:17
RT @lomu_j: $TBPH @BioStocks The $GSK position is not new FWIW. Same as in March http://t.co/iopFpJyeKn
j l
2 Sep 15 11:29:27
$TBPH @BioStocks The $GSK position is not new FWIW. Same as in March http://t.co/iopFpJyeKn
Navy Capital
2 Sep 15 11:24:30
RT @MarketCurrents: First patient dosed in Adaptimmune's expanded Phase 1/2 TCR study in rare cancer http://t.co/KiolJsUFS7 $ADAP $GSK
Ani Anirudhan
2 Sep 15 10:57:59
RT @BioStocks: $GSK reports 24.5% stake in $TBPH
Luke77
2 Sep 15 10:57:41
RT @BioStocks: $GSK reports 24.5% stake in $TBPH
HumbleBioTrader
2 Sep 15 10:55:24
RT @BioStocks: $GSK reports 24.5% stake in $TBPH
Abby Nachtomi
2 Sep 15 10:55:17
RT @BioStocks: $GSK reports 24.5% stake in $TBPH
Audi
2 Sep 15 10:54:48
RT @BioStocks: $GSK reports 24.5% stake in $TBPH
Jay
2 Sep 15 10:53:32
RT @BioStocks: $GSK reports 24.5% stake in $TBPH
Bio Stocks™
2 Sep 15 10:53:16
$GSK reports 24.5% stake in $TBPH
Zimfara Janus
2 Sep 15 10:40:04
@drpaulmorgan @richardhorton1 he's not pointing out problems, DrDaft, it's FRAUD - drug #fraud see also $GSK #MRK @NHS #homeopathy #FTW
Sweet Platform
2 Sep 15 10:18:21
GSK Top news - Sep 2nd, 2015 $GSK http://t.co/HfqPPVPC1u
Bull Logic
2 Sep 15 10:10:29
RT @sfef84: $TBPH there we go... 24M float $GSK 25% passive stake just filed now 14.33 gapped up
Steve Feffer
2 Sep 15 10:09:35
$TBPH there we go... 24M float $GSK 25% passive stake just filed now 14.33 gapped up
ProTradersNews
2 Sep 15 09:50:03
$GSK: New SEC Filing for GSK: Form SC 13G (No. 0000903423-15-000540): http://t.co/aCtYSYRfWO
SEC Filings
2 Sep 15 09:49:10
NEW SEC Filing for $GSK filed a moment ago: http://t.co/mRfum6LZXV http://t.co/FzpkSv2RXe
DJ Olive
2 Sep 15 09:40:57
RT @MarketCurrents: First patient dosed in Adaptimmune's expanded Phase 1/2 TCR study in rare cancer http://t.co/KiolJsUFS7 $ADAP $GSK
Taylor Ek
2 Sep 15 09:36:48
RT @MarketCurrents: First patient dosed in Adaptimmune's expanded Phase 1/2 TCR study in rare cancer http://t.co/KiolJsUFS7 $ADAP $GSK
conkers
2 Sep 15 09:35:24
#GSK +1% £13.19p @PharmaNewsDaily Indian drugmaker Sun #Pharma acquires $GSK's opiates business in Australia http://t.co/l81qk3EytK #YIELD
HumbleBioTrader
2 Sep 15 09:32:36
RT @MarketCurrents: First patient dosed in Adaptimmune's expanded Phase 1/2 TCR study in rare cancer http://t.co/KiolJsUFS7 $ADAP $GSK
Nara
2 Sep 15 09:29:24
$GSK $BMRN $IMGN $PSTI $OMER $DPRX JBEM Glioblastoma Data Trade. Read full DD here: https://t.co/gv9He7HRvh
Seeking Alpha
2 Sep 15 09:20:39
First patient dosed in Adaptimmune's expanded Phase 1/2 TCR study in rare cancer http://t.co/yvSYva6Ft3 $ADAP $GSK
Healthcare Stocks
2 Sep 15 09:20:39
First patient dosed in Adaptimmune's expanded Phase 1/2 TCR study in rare cancer http://t.co/FIBjzANyL5 $ADAP $GSK
Breaking News
2 Sep 15 09:20:38
First patient dosed in Adaptimmune's expanded Phase 1/2 TCR study in rare cancer http://t.co/KiolJsUFS7 $ADAP $GSK
Market Int Center
2 Sep 15 09:00:11
GlaxoSmithKline PLC $GSK Showing Bearish Technicals With Resistance At $40.30 ( http://t.co/Hd4fI3oCCW )
leahanne
2 Sep 15 08:35:10
Volume Alert - GSK 40.33 Glaxosmithkline Plc $GSK Hit a high today of 40.76 Closing the day 10:30 at 40.33 +0. http://t.co/qQqEj4kmBm
Peter Bardens
2 Sep 15 07:45:35
$GSK Should Gilead Sciences, Inc. Fear GlaxoSmithKline plc (ADR)? http://t.co/awvytUJZ1t
clayton
2 Sep 15 07:11:42
GSK 40.59 Glaxosmithkline Plc $GSK added to my watch list. Right now with GSK I am watching the last price 40. http://t.co/EFskxIGazs
iHangout
2 Sep 15 07:09:40
jim50: The Hot Zone: GSK Gapped up +0.66 $GSK Last Price 40.69 Day http://t.co/1fLWxMqdIS
jim50
2 Sep 15 07:03:30
GSK Gapped up +0.66 $GSK Last Price 40.69 Day High 40.69 Day Low 40.68 Change +1.22 Volume 88,342 Today 54 sto http://t.co/ApA70MjzjY
				
				
  +Follow August 16, 2013 9:54AM
Share:

Comments

 

blog comments powered by Disqus

 Today's Must Reads

Welcome to Equities.com's Small-Cap Throwdown


These Analysts Called Apple's (AAPL) Collapse, Here's What They're Saying Now

7 Dow Stocks Worth Owning and a Lot that Aren't

Sprint Turnaround Has Begun


Saving the

Small-Cap Market

 

Small-cap stocks offer investors many benefits, ranging from higher growth potential to overlooked value opportuni... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN